[1] 宋润波, 孟增智, 贾清雨.  分化型甲状腺癌的治疗新进展[J]. 现代中西医结合杂志, 2015, 24(24): 2728-2730.   doi: 10.3969/j.issn.1008-8849.2015.24.043
Song RB, Meng ZZ, Jia QY.  Recent advances in the treatment of differentiated thyroid cancer[J]. Mod J Integr Tradit Chin West Med, 2015, 24(24): 2728-2730.   doi: 10.3969/j.issn.1008-8849.2015.24.043
[2] 江晶晶, 王建华, 丁文波, 等.  FNAC联合BRAFV600E基因检测对甲状腺癌颈部淋巴结转移的诊断价值[J]. 中国普外基础与临床杂志, 2018, 25(9): 1083-1086.   doi: 10.7507/1007-9424.201801056
Jiang JJ, Wang JH, Ding WB, et al.  Diagnostic significance of fine needle aspiration cytology combined with BRAFV600E gene detection in cervical lymph node metastasis of thyroid cancer[J]. Chin J Bases Clin Gen Surg, 2018, 25(9): 1083-1086.   doi: 10.7507/1007-9424.201801056
[3]

Jegerlehner S, Bulliard JL, Aujesky D, et al. Overdiagnosis and overtreatment of thyroid cancer: A population-based temporal trend study[J/OL]. PLoS One, 2017, 12(6): e0179387[2018-12-26]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179387. DOI: 10.1371/journal.pone.0179387.
[4] 李继勇, 罗琦, 吴惠红.  分化型甲状腺癌术后复发转移的监测指标及影响因素分析[J]. 中国临床研究, 2017, 30(1): 69-71.   doi: 10.13429/j.cnki.cjcr.2017.01.020
Li JY, Luo Q, Wu HH.  Analysis of monitoring indicators and influencing factors of recurrence and metastasis of differentiated thyroid cancer after operation[J]. Chin J Clin Res, 2017, 30(1): 69-71.   doi: 10.13429/j.cnki.cjcr.2017.01.020
[5] 马宁帅.  血清Tg阳性/131I全身扫描阴性的分化型甲状腺癌诊治进展[J]. 生物医学工程学杂志, 2015, 32(3): 707-711.   doi: 10.7507/1001-5515.20150129
Ma NS.  Advances in Diagnosis and Treatment of Differentiated Thyroid Cancer in Patients Showing Thyroglobul in Elevative and Iodine Scintigraphy Negative[J]. J Biomed Eng, 2015, 32(3): 707-711.   doi: 10.7507/1001-5515.20150129
[6] 史良凤, 关海霞, 李玉姝, 等.  术前血清促甲状腺素水平与甲状腺结节良恶性关系的研究[J]. 中华内分泌代谢杂志, 2010, 26(3): 213-214.   doi: 10.3760/cma.j.issn.1000-6699.2010.03.011
Shi LF, Guan HX, Li YS, et al.  Association of preoperative serum thyrotropin level with benign or malignant thyroid nodules[J]. Chin J Endocrinol Metab, 2010, 26(3): 213-214.   doi: 10.3760/cma.j.issn.1000-6699.2010.03.011
[7] Kim ES, Lim DJ, Baek KH, et al.  Thyroglobulin Antibody is Associated with Increased Cancer Risk in Thyroid Nodules[J]. Thyroid, 2010, 20(8): 885-891.   doi: 10.1089/thy.2009.0384
[8] 周琼, 陈森良, 罗淼, 等.  血清Tg和TgAb水平监测在分化型甲状腺癌患者131I清甲治疗中的临床意义[J]. 中国医学前沿杂志（电子版）, 2017, 9(9): 105-108.   doi: 10.12037/YXQY.2017.09-25
Zhou Q, Chen SL, Luo M, et al.  Clinical significance of the levels of serum Tg and TgAb in the 131I ablation therapy for patients with differentiated thyroid cancer[J]. Chin J Front Med Sci（Electron Vers）, 2017, 9(9): 105-108.   doi: 10.12037/YXQY.2017.09-25
[9] 胡霜, 吉婷, 刘斌, 等.  分化型甲状腺癌患者清甲疗效评价中Tg阴性和诊断性全身显像阳性的临床意义[J]. 中华核医学与分子影像杂志, 2015, 35(2): 154-156.   doi: 10.3760/cma.j.issn.2095-2848.2015.02.019
Hu S, Ji T, Liu B, et al.  Clinical significance of negative thyroglobulin and positive diagnostic whole body scan in patients with differentiated thyroid carcinoma who underwent thyroid remnant ablation[J]. Chin J Nucl Med Mol Imaging, 2015, 35(2): 154-156.   doi: 10.3760/cma.j.issn.2095-2848.2015.02.019
[10] Netzel BC, Grebe SKG, Carranza Leon BG, et al.  Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes[J]. J Clin Endocrinol Metab, 2015, 100(8): E1074-E1083.   doi: 10.1210/jc.2015-1967
[11] 戴庆靖, 匡安仁.  甲状腺球蛋白测定的临床意义及影响因素[J]. 同位素, 2007, 20(2): 120-124.   doi: 10.3969/j.issn.1000-7512.2007.02.014
Dai QJ, Kuang AR.  The Clinical Application and Interference Factors of Serum Thyroglobulin Measurement[J]. J Isotopes, 2007, 20(2): 120-124.   doi: 10.3969/j.issn.1000-7512.2007.02.014
[12] Lee EK, Chung KW, Min HS, et al.  Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules[J]. J Korean Med Sci, 2012, 27(9): 1014-1018.   doi: 10.3346/jkms.2012.27.9.1014
[13]

Petric R, Besic H, Besic N. Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hurthle cell neoplasms of the thyroid gland[J/OL]. World J Surg Oncol, 2014, 12: 282[2018-12-26]. https://link.springer.com/article/10.1186/1477-7819-12-282. DOI: 10.1186/1477−7819−12−282.
[14] Giovanella L, Clark PM, Chiovato L, et al.  Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper[J]. Eur J Endocrinol, 2014, 171(2): R33-R46.   doi: 10.1530/EJE-14-0148
[15] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[16] Haugen BR.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?[J]. Cancer, 2017, 123(3): 372-381.   doi: 10.1002/cncr.30360
[17] Gurleyik E, Dogan S.  Accuracy of Unstimulated Basal Serum Thyroglobulin Levels in Assessing the Completeness of Thyroidectomy[J]. J Clin Med Res, 2014, 6(5): 369-373.   doi: 10.14740/jocmr1873w
[18] Spaas M, Decallonne B, Laenen A, et al.  Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer[J]. Eur Thyroid J, 2018, 7(4): 211-217.   doi: 10.1159/000489849
[19] Krajewska J, Jarząb M, Czarniecka A, et al.  Ongoing risk stratification for differentiated thyroid cancer (DTC)-stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients[J]. Endokrynol Pol, 2016, 67(1): 2-11.   doi: 10.5603/EP.2016.0001
[20] Park HJ, Jeong GC, Kwon SY, et al.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma[J]. Nucl Med Mol Imaging, 2014, 48(4): 255-261.   doi: 10.1007/s13139-014-0282-4
[21]

朱佩玲. 探讨分化型甲状腺癌术后复发转移的监测指标及影响因素[D]. 石家庄: 河北医科大学, 2014: 1−40.

Zhu PL. Explore Monitoring Index and Influencing Factors of the Postoperative Recurrence and Metastasis of Differentiated Thyroid Cancer[D]. Shijiazhuang: Hebei Medical University, 2014: 1−40.
[22] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I therapy of differentiated thyroid cancer(2014)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[23] 林岩松, 李娇.  2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读: 分化型甲状腺癌131I治疗新进展[J]. 中国癌症杂志, 2016, 26(1): 1-12.   doi: 10.3969/j.issn.1007-3969.2016.01.001
Lin YS, Li J.  The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New Progress in Radioactive Iodine-131 Therapy of Differentiated Thyroid Carcinoma[J]. China Oncol, 2016, 26(1): 1-12.   doi: 10.3969/j.issn.1007-3969.2016.01.001
[24] Stevic I, Dembinski TC, Pathak KA, et al.  Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer[J]. Clin Biochem, 2015, 48(10/11): 658-661.   doi: 10.1016/j.clinbiochem.2015.04.009
[25] Choi JH, Lim I, Lee I, et al.  An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy[J]. Ann Nucl Med, 2019, 33(2): 128-134.   doi: 10.1007/s12149-018-1313-5
[26] Dekker BL, van der Horst-Schrivers ANA, Sluiter WJ, et al.  Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity[J]. Thyroid, 2019, 29(1): 71-78.   doi: 10.1089/thy.2018.0195
[27] Jo K, Lim DJ.  Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer[J]. Korean J Intern Med, 2018, 33(6): 1050-1057.   doi: 10.3904/kjim.2018.289
[28] Matrone A, Latrofa F, Torregrossa L, et al.  Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without 131I Ablation[J]. Thyroid, 2018, 28(7): 871-879.   doi: 10.1089/thy.2018.0080
[29]

张莹. 分化型甲状腺癌术后131I治疗疗效分析及TgAb监测在预后评估的意义[D]. 郑州: 郑州大学, 2018: 1−49.

Zhang Y. The Efficacy of 131I Therapy for Postoperative Differentiated Thyroid Carcinoma and Significance of TgAb in Monitoring and Evaluating the Prognosis[D]. Zhengzhou: Zhengzhou University, 2018: 1−49.
[30] Spencer C, Fatemi S.  Thyroglobulin antibody (TgAb) methods-Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2013, 27(5): 701-712.   doi: 10.1016/j.beem.2013.07.003
[31] Kim WG, Yoon JH, Kim WB, et al.  Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma[J]. J Clin Endocrinol Metab, 2008, 93(12): 4683-4689.   doi: 10.1210/jc.2008-0962
[32]

张娜. 有关甲状腺球蛋白抗体与甲状腺乳头状癌131I治疗疗效关系的系列研究[D]. 青岛: 青岛大学, 2018: 1−53.

Zhang N. Series Research on the Impact of Thyroglobulin Antibody on Efficacy of Radioactive iodine Therapy in Patients with Papillary Thyroid Carcinoma[D]. Qingdao: Qingdao University, 2018: 1−53.